In this week's podcast edition of Five Must-Know Things: a market snapshot of inflammatory bowel disease; will biotech bounce back in 2023?; Phase III miss for Roche’s Alzheimer’s candidate; how Japan’s top firms did in the quarter; and China showcase hints at policies and strategies.

Among Vaxxinity’s immunotherapeutic vaccine candidates are one for Alzheimer’s that shows a 50% reduction in cognitive decline, another that shows superior durability than Pfizer and Moderna’s COVID-19 vaccines and one that could prevent migraines. Vaxxinity CEO speaks to Scrip about these and more in this interview

After inking major deals with AbbVie and AstraZeneca, China-US company Harbour BioMed recently shifted strategy, divesting its site in Suzhou to WuXi in a bid to be “more focused, efficient and nimble” and emerge stronger post-pandemic, says founder, chairman and CEO Jingsong Wang in an exclusive interview.

In this week's podcast version of Five Must-Know Things: Pfizer’s COVID transition; Lilly ramps up Mounjaro on strong demand; Pfizer’s R&D head reflects on pandemic experience; parsing Novartis’s Q3; and China’s progress with mRNA vaccines.

International Vaccine Institute Director General Jerome Kim talks to Scrip about the significance of South Korea's vaccine hub strategy and IVI's role, as well as the wider progress in the sector in the country.

China's once-in-five-years Communist Party National Congress and new leadership, as well as new guidelines on therapeutic cancer vaccines, are the main topics for this new China Biotech Hot Topic podcast. Brian Yang and Dexter Yan discuss key points to watch and the implications for major players and the wider pharma sector.

In this week's podcast edition of Five Must-Know Things: BMS looks to new launches amid patent losses; Novartis prioritizes high-value medicines and the US market; Biogen learns from Aduhelm experience; J&J builds myeloma franchise; and Asian bioventures debate best strategies.

In this week's podcast edition of Five Must-Know Things: J&J and Roche’s first-half wins and challenges; Alexion’s Ultomiris plans; GSK’s AI and genomics investments; and a wide-ranging chat with the former secretary of the US department of Veterans Affairs.